KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Amortization of Deferred Charges: 2013-2022

Historic Amortization of Deferred Charges for TherapeuticsMD (TXMD) over the last 5 years, with Sep 2022 value amounting to $2.6 million.

  • TherapeuticsMD's Amortization of Deferred Charges rose 74.81% to $2.6 million in Q3 2022 from the same period last year, while for Sep 2022 it was $21.1 million, marking a year-over-year increase of 317.92%. This contributed to the annual value of $5.7 million for FY2021, which is 124.68% up from last year.
  • As of Q3 2022, TherapeuticsMD's Amortization of Deferred Charges stood at $2.6 million, which was down 67.41% from $7.9 million recorded in Q2 2022.
  • In the past 5 years, TherapeuticsMD's Amortization of Deferred Charges ranged from a high of $9.0 million in Q1 2022 and a low of $119,753 during Q3 2018.
  • Moreover, its 3-year median value for Amortization of Deferred Charges was $1.4 million (2021), whereas its average is $2.5 million.
  • Data for TherapeuticsMD's Amortization of Deferred Charges shows a peak YoY skyrocketed of 611.32% (in 2022) over the last 5 years.
  • Over the past 5 years, TherapeuticsMD's Amortization of Deferred Charges (Quarterly) stood at $119,950 in 2018, then skyrocketed by 127.74% to $273,171 in 2019, then surged by 224.71% to $887,000 in 2020, then spiked by 72.60% to $1.5 million in 2021, then surged by 74.81% to $2.6 million in 2022.
  • Its Amortization of Deferred Charges was $2.6 million in Q3 2022, compared to $7.9 million in Q2 2022 and $9.0 million in Q1 2022.